Loading…
Company reports significant neutralization potency and protection rates.
Invivyd, Inc. announced on 2025-02-03 Invivyd announced positive Phase 1/2 clinical data for VYD2311, a monoclonal antibody designed to be a superior alternative to COVID-19 vaccination, with results compared to placebo.
17-fold greater neutralization potency. The announcement cited 40 subjects, 3 routes of administration, 70-90% protection, once- or twice-annual dosing, $13.8 million, 48% growth, and 55% reduction.
Invivyd, Inc. has a free float of 117,543,000 shares and 233,123,000 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.